{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:12Z","timestamp":1777870332486,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padova","doi-asserted-by":"crossref","award":["DOR 2208432\/2022"],"award-info":[{"award-number":["DOR 2208432\/2022"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-01934-7","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T09:01:46Z","timestamp":1718442106000},"page":"1201-1207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oxidative stress and its role in Fabry disease"],"prefix":"10.1093","volume":"37","author":[{"given":"Martina","family":"Cacciapuoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Bertoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Driussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-0128","authenticated-orcid":false,"given":"Lorenzo A.","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"1934_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, Rolfs A (2013) Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genet 9:e1003632.2","journal-title":"PLoS Genet"},{"key":"1934_CR2","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","volume":"285","author":"AI Guce","year":"2010","unstructured":"Guce AI, Clark NE, Salgado N, Ivanen DR, Kulminskaya AA, Brumer H, Garman SC (2010) Catalytic mechanism of human a-galactosidase. J Biol Chem 285:3625\u20133632","journal-title":"J Biol Chem"},{"key":"1934_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/EBC20190090","volume":"64","author":"M Van Eijk","year":"2020","unstructured":"Van Eijk M, Ferraz MJ, Boot RG, Aerts JMFG (2020) Lyso-glycosphingolipids: presence and consequences. Essays Biochem 64:565\u2013578","journal-title":"Essays Biochem"},{"key":"1934_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:1\u201349","journal-title":"Orphanet J Rare Dis"},{"key":"1934_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak E (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47","journal-title":"Orphanet J Rare Dis"},{"key":"1934_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/jcm7110409","volume":"7","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Simioni F, Carraro G, Bertoldi G, Pagnin E, Cal\u00f2 LA (2018) Oxidative stress and cardiovascular-renal damage in Fabry disease: is there room for a pathophysiological involvement? J Clin Med 7:409","journal-title":"J Clin Med"},{"key":"1934_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S (2017) Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab 122:19\u201327","journal-title":"Mol Genet Metab"},{"key":"1934_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","volume":"30","author":"MH Lee","year":"2012","unstructured":"Lee MH, Choi N, Jeo YJ, Jung SC (2012) Possible role of transforming growth factor-B1 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mo Med 30:1275\u20131280","journal-title":"Int J Mo Med"},{"key":"1934_CR9","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Ni\u00f1o","year":"2011","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A et al (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26:1797\u20131802","journal-title":"Nephrol Dial Transplant"},{"key":"1934_CR10","doi-asserted-by":"publisher","first-page":"e0136442","DOI":"10.1371\/journal.pone.0136442","volume":"10","author":"YJ Jeon","year":"2015","unstructured":"Jeon YJ, Jun N, Park J-W, Park HY, Jung SC (2015) Epithelial\u2013mesenchymal transition in kidney tubular epithelial cells induced by globotriaosylsphingosine and globotriaosylceramide. PLoS ONE 10:e0136442","journal-title":"PLoS ONE"},{"issue":"1221","key":"1934_CR11","first-page":"e1-1221.e9","volume":"32","author":"KH Chen","year":"2016","unstructured":"Chen KH, Chien Y, Wang KL, Leu HB, Hsiao CY, Lai YH, Wang CY, Chang YL, Lin SJ, Niu DM, Chiou SH, Yu WC (2016) Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 32(1221):e1-1221.e9","journal-title":"Can J Cardiol"},{"key":"1934_CR12","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","volume":"38","author":"Y Hayashi","year":"2015","unstructured":"Hayashi Y, Hanawa H, Jiao S, Hasegawa G, Ohno Y, Yoshida K, Suzuki T, Kashimura T, Obata H, Tanaka K, Watanabe T, Minamino T (2015) Elevated endomyocardial biopsy macrophage-related markers in intractable myocardial diseases. Inflammation 38:2288\u20132299","journal-title":"Inflammation"},{"key":"1934_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.lfs.2018.08.067","volume":"210","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Simioni F, Pagnin E, Davis PA, Cal\u00f2 LA (2018) Oxidative stress-chronic kidney disease-cardiovascular disease: a vicious circle. Life Sci 210:125\u2013131","journal-title":"Life Sci"},{"key":"1934_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/antiox10071041","volume":"10","author":"V Ravarotto","year":"2021","unstructured":"Ravarotto V, Bertoldi G, Innico G, Gobbi L, Cal\u00f2 LA (2021) The pivotal role of oxidative stress in the pathophysiology of cardiovascular-renal remodeling in kidney disease. Antioxidants 10:1041","journal-title":"Antioxidants"},{"key":"1934_CR15","doi-asserted-by":"publisher","first-page":"e0204618","DOI":"10.1371\/journal.pone.0204618","volume":"13","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Carraro G, Pagnin E, Bertoldi G, Simioni F, Maiolino G, Martinato M, Landini L, Davis PA, Cal\u00f2 LA (2018) Oxidative stress and the altered reaction to it in Fabry disease: a possible target for cardiovascular-renal remodeling? PLoS One 13:e0204618","journal-title":"PLoS One"},{"key":"1934_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E (2021) Fabry disease: the current treatment landscape. Drugs 81:635\u2013645","journal-title":"Drugs"},{"key":"1934_CR17","volume-title":"Oxidative stress","author":"H Sies","year":"1985","unstructured":"Sies H et al (1985) Oxidative stress. Academic Press, London, UK"},{"key":"1934_CR18","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24:R453","journal-title":"Curr Biol"},{"key":"1934_CR19","doi-asserted-by":"publisher","first-page":"360438","DOI":"10.1155\/2014\/360438","volume":"2014","author":"A Ayala","year":"2014","unstructured":"Ayala A, Mu\u00f1oz MF, Arg\u00fcelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014:360438","journal-title":"Oxid Med Cell Longev"},{"key":"1934_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.23876\/j.krcp.22.069","volume":"41","author":"V Ravarotto","year":"2022","unstructured":"Ravarotto V, Bertoldi G, Stefanelli LF, Nalesso F, Cal\u00f2 LA (2022) Pathomechanism of oxidative stress in cardiovascular renal remodeling and therapeutic strategies. Kidney Res Clin Pract 41:533\u2013544","journal-title":"Kidney Res Clin Pract"},{"key":"1934_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"JS Shen","year":"2008","unstructured":"Shen JS, Meng XL, Moore DF, Quirk JM, Shayma JA, Schiffmann R, Kaneski CR (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95:163\u2013168","journal-title":"Mol Genet Metab"},{"key":"1934_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0009-8981(03)00191-8","volume":"334","author":"CC Chiou","year":"2003","unstructured":"Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, Wu JT (2003) Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 334:87\u201394","journal-title":"Clin Chim Acta"},{"key":"1934_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbrc.2017.03.030","volume":"486","author":"KH Chen","year":"2017","unstructured":"Chen KH, Chou YC, Hsiao CY, Chien Y, Wang KL, Lai YH, Chang YL, Niu DM, Yu WC (2017) Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with fabry cardiomyopathy. Biochem Biophys Res Commun 486:293\u2013299","journal-title":"Biochem Biophys Res Commun"},{"key":"1934_CR24","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","volume":"46","author":"C Chimenti","year":"2015","unstructured":"Chimenti C, Scopelliti F, Vulpis E, Tafani M, Villanova L, Verardo R, De Paulis R, Russo MA, Frustaci A (2015) Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. Hum Pathol 46:1760\u20131768","journal-title":"Hum Pathol"},{"key":"1934_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mrgentox.2015.04.012","volume":"784\u2013785","author":"GB Biancini","year":"2015","unstructured":"Biancini GB, Moura DJ, Manini PR, Faverzani JL, Netto CB, Deon M, Giugliani R, Saffi J, Vargas CR (2015) DNA damage in Fabry patients: an investigation of oxidative damage and repair. Mutat Res Genet Toxicol Environ Mutagen 784\u2013785:31\u201336","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"1934_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/ki.2013.520","volume":"86","author":"L Shu","year":"2014","unstructured":"Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, Shayman JA (2014) Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int 86:58\u201366","journal-title":"Kidney Int"},{"key":"1934_CR27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/hmg\/ddx032","volume":"26","author":"JS Shen","year":"2017","unstructured":"Shen JS, Arning E, West ML, Day S, Chen S, Meng XL, Forni S, McNeill N, Goker- Alpan O, Wang X, Ashcraft P, Moore DF, Cheng SH, Schiffmann R, Bottiglieri T (2017) Tet-rahydrobiopterin deficiency in the pathogenesis of Fabry disease. Hum Mol Genet 26:1182\u20131192","journal-title":"Hum Mol Genet"},{"key":"1934_CR28","doi-asserted-by":"publisher","first-page":"e36373","DOI":"10.1371\/journal.pone.0036373","volume":"7","author":"M Namdar","year":"2012","unstructured":"Namdar M, Gebhard C, Studiger R, Shi Y, Mocharla P, Schmied C, Brugada P, L\u00fcscher TF, Camici GC (2012) Glo-botriaosylsphingosine accumulation and not alpha-galactosidase-a deficiency causes endothelial dysfunction in Fabry disease. PloS ONE 7:e36373","journal-title":"PloS ONE"},{"key":"1934_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.abb.2009.11.019","volume":"494","author":"J Sun","year":"2010","unstructured":"Sun J, Druhan LJ, Zweier JL (2010) Reactive oxygen and nitrogen species regulate inducible nitric oxide synthase function shifting the balance of nitric oxide and superoxide production. Arch Biochem Biophys 494:130\u2013137","journal-title":"Arch Biochem Biophys"},{"key":"1934_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","volume":"111","author":"PF Bodary","year":"2005","unstructured":"Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S (2005) Alpha-galactosidase a deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629\u2013632","journal-title":"Circulation"},{"key":"1934_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, Manfredini V, Netto CBO, Jardim LB, Giugliani R, Vargas CR (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 1822:226\u2013232","journal-title":"Biochim Biophys Acta"},{"key":"1934_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/01.RES.86.5.494","volume":"86","author":"KK Griendling","year":"2000","unstructured":"Griendling KK, Soresen D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494\u2013501","journal-title":"Circ Res"},{"key":"1934_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/HJH.0b013e328010d4d2","volume":"25","author":"LA Cal\u00f2","year":"2007","unstructured":"Cal\u00f2 LA, Pessina AC (2007) RhoA\/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 25:259\u2013264","journal-title":"J Hypertens"},{"key":"1934_CR34","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/jcm9051328","volume":"9","author":"TM Seccia","year":"2020","unstructured":"Seccia TM, Rigato M, Ravarotto V, Cal\u00f2 LA (2020) ROCK (RhoA\/Rho kinase) in cardiovascular\u2013renal pathophysiology: a review of new advancements. J Clin Med 9:1328","journal-title":"J Clin Med"},{"key":"1934_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/HYPERTENSIONAHA.107.092296","volume":"50","author":"SR Datla","year":"2007","unstructured":"Datla SR, Dusting GJ, Mori TA, Taylor CJ, Croft KD, Jiang F (2007) Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 50:636\u2013642","journal-title":"Hypertension"},{"key":"1934_CR36","doi-asserted-by":"publisher","first-page":"924710","DOI":"10.3389\/fnut.2022.924710","volume":"9","author":"G Bertoldi","year":"2022","unstructured":"Bertoldi G, Carraro G, Ravarotto V, Di Vico V, Baldini Anastasio P, Vitturi N, Francini F, Stefanelli LF, Cal\u00f2 LA (2022) The effect of green tea as an adjuvant to enzyme replacement therapy on oxidative stress in Fabry disease: a pilot study. Front Nutr 9:924710","journal-title":"Front Nutr"},{"key":"1934_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-St\u00e5hl E, Hughes DA, Kampmann C, Mehta AB, Nicholls K, Niu DM, Pintos-Morell G, Reisin R, West ML, Schenk J, Anagnostopoulou C, Botha J, Giugliani R (2022) Twenty years of the Fabry outcome survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis 17:238","journal-title":"Orphanet J Rare Dis"},{"key":"1934_CR38","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.ymgme.2022.106967","volume":"138","author":"RJ Hopkin","year":"2023","unstructured":"Hopkin RJ, Cabrera GH, Jefferies JL, Yang M, Ponce E, Brand E, Feldt-Rasmussen U, Germain DP, Guffon N, Jovanovic A, Kantola I, Karaa A, Martins AM, T\u00f8ndel C, Wilcox WR, Yoo HW, Burlina AP, Mauer M (2023) Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry. Mol Genet Metab 138:106967","journal-title":"Mol Genet Metab"},{"key":"1934_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1399-0004.1987.tb02820.x","volume":"31","author":"H Sakuraba","year":"1987","unstructured":"Sakuraba H, Igarashi T, Shibata T, Suzuki Y (1987) Effect of vitamin E and ticlopidine on platelet aggregation in Fabry\u2019s disease. Clin Genet 31:349\u2013354","journal-title":"Clin Genet"},{"key":"1934_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/jmri.20162","volume":"20","author":"DF Moore","year":"2004","unstructured":"Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, Rhead WJ, Brady RO, Hazen SL, Schiffmann R et al (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 20:674\u2013683","journal-title":"J Magn Reson Imaging"},{"key":"1934_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"461","author":"GB Biancini","year":"2016","unstructured":"Biancini GB, Jacques CE, Hammerschmidt T, de Souza HM, Donida B, Deon M, Vairo FP, Louren\u00e7o CM, Giugliani R, Vargas CR (2016) Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta 461:41\u201346","journal-title":"Clin Chim Acta"},{"key":"1934_CR42","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","volume":"53","author":"JW Kim","year":"2021","unstructured":"Kim JW, Kim HW, Nam SA, Lee JY, Cho HJ, Kim TM, Kim YK (2021) Human kidney organoids reveal the role of glutathione in Fabry disease. Exp Mol Med 53:1580\u20131591","journal-title":"Exp Mol Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-01934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:46Z","timestamp":1777564426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/5\/1201\/8306717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-01934-7","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required as this review includes a synthesis and analysis of existing studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}